Octagon Capital Advisors LP / TSHA
Octagon Capital Advisors LP’s Taysha Gene Therapies Inc Position
Does Octagon Capital Advisors LP own Taysha Gene Therapies Inc (TSHA)? Yes — 8.86M shares worth $40M (+4.38% of its 13F portfolio) as of Q1 2026.
Position Value
$40M
Q1 2026
Shares
8.86M
% of Portfolio
+4.38%
Quarters Held
13
currently held
Position History TSHA
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 8.86M | $40M | +4.38% |
| Q4 2025 | 8.86M | $49M | +5.92% |
| Q3 2025 | 9.07M | $30M | +4.49% |
| Q2 2025 | 12.59M | $29M | +6.38% |
| Q1 2025 | 10.70M | $15M | +2.88% |
| Q4 2024 | 10.45M | $18M | +2.97% |
| Q3 2024 | 4.57M | $9M | +1.43% |
| Q2 2024 | 4.57M | $10M | +1.61% |
| Q1 2024 | 3.03M | $9M | +1.04% |
| Q3 2023 | 2.78M | $9M | +1.35% |
| Q2 2021 | 320.4K | $7M | +1.41% |
| Q1 2021 | 320.4K | $7M | +2.45% |
| Q4 2020 | 320.4K | $9M | +2.95% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Octagon Capital Advisors LP’s full portfolio or all institutional holders of TSHA.